drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (genetically modified autologous TCR-T cells)
drug_description
Autologous, genetically modified TCR-T cell therapy engineered to express an affinity-enhanced T-cell receptor that recognizes MAGE-A4 peptide presented by HLA-A*02; administered as a single weight-based IV infusion to mediate antigen-specific cytotoxicity via TCR/CD3 signaling, perforin/granzyme release, and cytokine secretion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Afamitresgene autoleucel
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express an affinity-enhanced TCR that recognizes MAGE-A4 peptide presented by HLA-A*02 on tumor cells; TCR/CD3 engagement activates the T cells to mediate antigen-specific killing via perforin/granzyme release and cytokine secretion.
drug_name
Afamitresgene autoleucel (afami-cel)
nct_id_drug_ref
NCT05642455